GlassScriptPhysician profile
Danuta T Derkatz
NPI 1639144611
$1,983.80
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $716.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $352.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.48 | 2019-2020 | |
| Akebia Therapeutics INC | $208.62 | 2019 | |
| Amarin Pharma, INC. | $160.13 | 2019-2020 | |
| Astellas Pharma US INC | $154.05 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $119.77 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $117.91 | 2019-2020 | |
| Pfizer INC. | $114.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $94.50 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $82.61 | 2019-2020 | |
| Lilly USA, LLC | $82.35 | 2019 | |
| Sanofi-Aventis U.S. LLC | $75.53 | 2019 | |
| Alexion Pharmaceuticals, INC. | $50.19 | 2019-2020 | |
| Novo Nordisk INC | $31.25 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.05 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $20.79 | 2020 | |
| Amgen INC. | $17.84 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.03 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danuta Derkatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.